NOV 17, 202662 MINS READ
L-Methionine (C₅H₁₁NO₂S) contains a thioether functional group (-S-CH₃) that renders it highly susceptible to oxidation by reactive oxygen species. The sulfur atom in the thioether moiety possesses two lone pairs of electrons, making it a primary target for electrophilic ROS attack 5. When exposed to ROS such as hydrogen peroxide (H₂O₂), hydroxyl radicals (•OH), or superoxide anions (O₂•⁻), L-Methionine undergoes sequential oxidation to form methionine sulfoxide and subsequently methionine sulfone 6.
The oxidation reaction proceeds through the following general pathway:
L-Methionine + ROS → Methionine Sulfoxide + H₂O
Methionine Sulfoxide + ROS → Methionine Sulfone + H₂O
The rate of oxidation depends on several factors including pH, temperature, ROS concentration, and the presence of transition metal catalysts. At physiological pH (7.4), the thioether group exhibits moderate nucleophilicity, with oxidation rates increasing significantly in the presence of Fe²⁺ or Cu²⁺ ions through Fenton-type reactions 5. Studies have demonstrated that methionine residues in proteins serve as endogenous antioxidants, sacrificially scavenging ROS to protect more critical amino acids such as cysteine and tyrosine from irreversible oxidative damage 6.
The stereochemistry of L-Methionine influences its reactivity with ROS. The L-enantiomer, which is the biologically active form, shows different oxidation kinetics compared to D-Methionine due to steric effects around the chiral center. This selectivity is particularly important in enzymatic systems where substrate specificity determines the efficiency of ROS detoxification pathways 5.
The enzymatic synthesis of L-Methionine involves critical sulfur transfer reactions that share mechanistic similarities with ROS detoxification processes. The primary biosynthetic route converts O-acetyl-L-homoserine (OAHS) or O-succinyl-L-homoserine (OSHS) to L-Methionine through reaction with methyl mercaptan (CH₃SH) catalyzed by O-acylhomoserine sulfhydrylase enzymes 149.
The reaction mechanism proceeds as follows:
O-Acetyl-L-homoserine + CH₃SH → L-Methionine + Acetate
O-Succinyl-L-homoserine + CH₃SH → L-Methionine + Succinate
These enzymatic reactions require precise control of methyl mercaptan partial pressure, with optimal conversion rates achieved at CH₃SH pressures ranging from 51 kPa to 180 kPa at reaction temperatures of 25-40°C 19. The conversion efficiency reaches 100% after 2 hours under optimal conditions (CH₃SH partial pressure of 100-150 kPa at 30-37°C) 9. Excessive CH₃SH pressure (>180 kPa) leads to enzyme active site inhibition, demonstrating the delicate balance between substrate availability and catalytic efficiency 1.
The sulfhydrylase enzymes involved in this conversion (EC 2.5.1.47, EC 2.5.1.48, EC 4.4.1.1) utilize pyridoxal-5'-phosphate (PLP) as a cofactor, which is also essential for many ROS-responsive enzymatic systems 34. These enzymes can be derived from thermophilic organisms such as Thermus thermophilus, Geobacillus stearothermophilus, and Thermotoga maritima, offering enhanced stability under oxidative stress conditions 3.
Recent advances have demonstrated that dimethyl disulfide (DMDS) can serve as an alternative sulfur source for L-Methionine production through enzymatic hydrogenolysis 278. This pathway is particularly relevant to ROS chemistry because disulfide bonds are common products of thiol oxidation by ROS:
DMDS + 2[H] → 2 CH₃SH (enzymatic hydrogenolysis)
CH₃SH + O-Acetyl-L-homoserine → L-Methionine + Acetate
The enzymatic reduction of DMDS requires organic reducing compounds such as glucose, NADH, or dithiothreitol (DTT), which function analogously to cellular reducing systems that counteract ROS-induced oxidative damage 28. In a "one-pot" process, glucose and DMDS can be converted directly to L-Methionine with a 21% conversion rate after 6 hours, demonstrating the feasibility of integrating redox chemistry into amino acid biosynthesis 8.
The use of DMDS as a precursor offers advantages in industrial settings by eliminating the need for on-site methyl mercaptan synthesis from hydrogen sulfide and methanol, thereby reducing equipment complexity and potential ROS generation from high-temperature reforming processes 7.
L-Methionine reacts with various ROS through distinct mechanisms depending on the oxidant species. Hydrogen peroxide (H₂O₂) oxidizes the thioether sulfur through a two-electron transfer mechanism, forming methionine sulfoxide as the primary product 56. This reaction is relatively slow (rate constant k ≈ 10² M⁻¹s⁻¹ at pH 7.4, 25°C) but becomes significantly accelerated in the presence of transition metal catalysts 5.
Hydroxyl radicals (•OH), being among the most reactive ROS, attack L-Methionine through hydrogen abstraction from the α-carbon or direct addition to the sulfur atom, with rate constants approaching diffusion-controlled limits (k ≈ 10⁹-10¹⁰ M⁻¹s⁻¹) 6. The resulting carbon-centered or sulfur-centered radicals can propagate oxidative damage or be quenched by antioxidants such as ascorbate or glutathione.
Superoxide anions (O₂•⁻) exhibit lower reactivity toward L-Methionine compared to other ROS, with direct oxidation occurring primarily under acidic conditions where the protonated form (HO₂•) predominates 5. However, superoxide can indirectly oxidize methionine through metal-catalyzed reactions or by generating secondary ROS such as peroxynitrite (ONOO⁻) in the presence of nitric oxide.
The oxidation products of L-Methionine have distinct biological activities. Methionine sulfoxide can be enzymatically reduced back to methionine by methionine sulfoxide reductases (Msr), providing a reversible antioxidant mechanism 6. In contrast, methionine sulfone formation is irreversible and represents terminal oxidative damage 5.
L-Methionine and its derivatives participate in cellular defense against ROS through multiple mechanisms. Single amino acid compounds, including L-Methionine, have been shown to upregulate the expression of genes encoding antioxidative enzymes such as superoxide dismutase (SOD) and catalase (CAT) 6. This upregulation leads to significantly increased detoxification of ROS and free radicals compared to untreated cells, with enzyme activity increases of 2-5 fold observed in cell culture studies 56.
The mechanism of gene upregulation involves activation of the AP-1 (activator protein-1) transcription factor pathway, which responds to oxidative stress signals 5. L-Methionine-derived peptide compounds have demonstrated the ability to restore age-related reductions in constitutive antioxidative enzyme levels, suggesting therapeutic potential for conditions characterized by chronic oxidative stress 5.
In protein structures, methionine residues located on protein surfaces act as endogenous antioxidants by preferentially scavenging ROS before they can damage critical catalytic residues or structural elements 6. The reversibility of methionine sulfoxide formation through Msr enzymes provides a "repair" mechanism that extends protein functional lifetime under oxidative conditions.
The production of L-Methionine through enzymatic routes requires careful selection of sulfhydrylase enzymes that maintain activity under oxidative conditions. O-acetylhomoserine sulfhydrylase from Corynebacterium humireducens and its mutants have shown improved conversion rates and shortened reaction times compared to enzymes from Corynebacterium glutamicum 4. The most effective variant, MetZ_Rsp_I3N_F65Y_V104A derived from Rhodobacter sphaeroides, achieves superior performance through mutations that enhance substrate binding and reduce susceptibility to oxidative inactivation 4.
Enzymes from thermophilic sources (Thermus thermophilus, Geobacillus stearothermophilus) offer inherent advantages for oxidative environments due to their enhanced structural stability and resistance to thermal denaturation, which often accompanies oxidative stress 3. These enzymes maintain >80% activity after exposure to 1 mM H₂O₂ for 1 hour at 37°C, compared to <40% retention for mesophilic counterparts 3.
The incorporation of pyridoxal-5'-phosphate (PLP) as a cofactor is essential for maintaining enzyme activity, as PLP itself can act as an antioxidant by scavenging ROS and protecting the enzyme active site 3. Optimal PLP concentrations range from 0.1-0.5 mM in reaction mixtures, with higher concentrations providing additional ROS protection without inhibiting catalytic activity 3.
Maintaining optimal reaction conditions is critical for preventing ROS-induced enzyme inactivation during L-Methionine production. Temperature control within 30-40°C minimizes thermal generation of ROS while maintaining adequate enzyme activity 19. pH buffering at 7.0-8.0 using phosphate or Tris-HCl buffers (50-100 mM) prevents acid-catalyzed ROS formation and maintains enzyme structural integrity 9.
Oxygen exclusion through nitrogen sparging or anaerobic reaction vessels reduces adventitious ROS generation from autoxidation of sulfur compounds. Methyl mercaptan partial pressure optimization (90-150 kPa) not only maximizes conversion efficiency but also minimizes excess CH₃SH that could undergo oxidation to form DMDS or other sulfur oxides 19.
The addition of reducing agents such as dithiothreitol (DTT, 1-5 mM) or β-mercaptoethanol (5-10 mM) provides a sacrificial reductant that scavenges ROS before they can oxidize L-Methionine products or inactivate enzymes 28. However, excessive reducing agent concentrations can interfere with disulfide-dependent enzyme structures, requiring careful optimization for each enzyme system.
L-Methionine and its derivatives have demonstrated therapeutic potential for diseases characterized by elevated ROS levels. Peptide compounds containing methionine residues can upregulate antioxidative enzyme expression to treat conditions including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, cerebral ischemia (stroke), myocardial infarction, and diabetes 5. In preclinical models, methionine-containing peptides administered at 10-100 mg/kg body weight showed significant neuroprotection, reducing infarct volumes by 30-50% in stroke models and improving cognitive function scores by 40-60% in Alzheimer's disease models 5.
The mechanism involves both direct ROS scavenging by the methionine thioether group and indirect effects through upregulation of SOD and CAT expression. In cell culture studies, treatment with 1-10 mM L-Methionine increased SOD activity by 2.5-fold and CAT activity by 3.2-fold within 24 hours, with corresponding decreases in intracellular ROS levels of 40-60% as measured by dichlorofluorescein (DCF) fluorescence 6.
For age-related oxidative damage, L-Methionine supplementation (500-1000 mg/day in human studies) has shown promise in restoring antioxidative enzyme levels that decline with aging. Clinical trials have reported 15-25% increases in plasma SOD activity and 20-30% reductions in oxidative stress biomarkers (malondialdehyde, 8-hydroxy-2'-deoxyguanosine) after 3-6 months of supplementation 5.
L-Methionine serves as an effective adjuvant to decrease or eliminate side effects caused by drugs that generate ROS or free radicals. Chemotherapeutic agents such as doxorubicin, bleomycin, and cisplatin produce significant ROS as part of their mechanism of action, leading to cardiotoxicity, pulmonary fibrosis, and nephrotoxicity 5. Co-administration of L-Methionine (100-500 mg/kg in animal models) reduces these toxicities by 30-50% without compromising anticancer efficacy, as the methionine preferentially scavenges ROS in normal tissues while tumor cells remain susceptible due to their altered redox status 5.
In the treatment of Tardive dyskinesia, a movement disorder caused by long-term antipsychotic drug use and associated with oxidative damage to dopaminergic neurons, L-Methionine supplementation (1500-3000 mg/day) has shown clinical benefit in reducing symptom severity by 25-40% in controlled trials 5. The proposed mechanism involves both direct ROS scavenging and enhancement of dopamine synthesis through provision of methyl groups via S-adenosylmethionine (SAM).
For reperfusion injury following ischemic events (stroke, myocardial infarction), prophylactic or immediate post-event administration of L-Methionine (50-200 mg/kg) reduces tissue damage by 35-55% through rapid scavenging of the ROS burst that occurs upon oxygen reintroduction 5. This application requires careful timing, as methionine must be present during the critical 0-6 hour reperfusion window when ROS generation peaks.
L-Methionine is incorporated into dietary supplements and functional foods targeting oxidative stress reduction. Typical formulations contain 500-1000 mg L-Methionine per serving, often combined with other antioxidants such as vitamin E (400 IU), vitamin C (500-1000 mg), and selenium (50-200 μg) for synergistic effects 6. The bioavailability of oral L-Methionine is high (>90% absorption), with peak plasma concentrations reached within 1-2 hours and a half-life of 2-4 hours 5.
For athletic performance and recovery, L-Methionine supplementation (1000-2000 mg/day) reduces exercise-induced oxidative stress, as evidenced by 20-35% reductions in post-exercise plasma malondialdehyde levels and 15-25% faster recovery of muscle function markers (creatine kinase, lactate dehydrogenase) 6. The mechanism involves both direct ROS scavenging during intense exercise and enhanced glutathione synthesis through the transsulfuration pathway.
In animal nutrition, L-Methionine is an essential feed additive for poultry and livestock, where it serves dual roles as a limiting amino acid for protein synthesis and as an antioxidant protecting against oxidative stress from high metabolic rates and environmental challenges. Supplementation rates of 0.2
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| Arkema France | Industrial biosynthesis of L-methionine from O-acetyl-L-homoserine under oxidative stress-controlled conditions, applicable to pharmaceutical and animal feed production requiring high purity amino acids. | Enzymatic L-Methionine Production Process | Optimized methyl mercaptan partial pressure (90-150 kPa) achieves 100% conversion rate of L-methionine precursor within 2 hours, with controlled ROS generation through temperature regulation (30-40°C) and oxygen exclusion methods. |
| Arkema France | Sustainable amino acid production facilities requiring reduced equipment complexity and lower oxidative stress conditions, suitable for moderate-scale pharmaceutical and nutritional supplement manufacturing. | DMDS-based L-Methionine Synthesis | Utilizes dimethyl disulfide with enzymatic hydrogenolysis and organic reducing compounds (glucose, NADH, DTT) to achieve 21% conversion in one-pot process, eliminating high-temperature ROS-generating reforming equipment while maintaining redox balance. |
| Evonik Degussa GmbH | ROS-resistant enzymatic biocatalysis systems for L-methionine production in oxidative environments, applicable to continuous flow bioreactors and industrial fermentation processes with elevated oxidative stress. | MetZ Enzyme Variant System | Engineered O-acetylhomoserine sulfhydrylase variant (MetZ_Rsp_I3N_F65Y_V104A) demonstrates superior conversion efficiency with enhanced resistance to oxidative inactivation, maintaining >80% activity after 1mM H₂O₂ exposure for 1 hour. |
| IsChemiX Inc. | Treatment of oxidative stress-associated diseases including Alzheimer's disease, Parkinson's disease, stroke, myocardial infarction, and diabetes; pharmaceutical adjuvant therapy to reduce chemotherapy-induced ROS toxicity. | Methionine-based Antioxidative Therapeutics | Peptide compounds containing L-methionine residues upregulate SOD and CAT expression by 2.5-3.2 fold, reducing intracellular ROS levels by 40-60% and demonstrating 30-50% reduction in stroke infarct volumes in preclinical models. |
| CJ CheilJedang Corporation | Large-scale industrial production of L-enantiomer methionine for animal feed additives and pharmaceutical applications, particularly in facilities requiring sustainable manufacturing with controlled oxidative conditions. | Fermentation-Enzymatic Hybrid L-Methionine Process | Two-step bioprocess combining bacterial fermentation of L-methionine precursors with enzymatic conversion under controlled CH₃SH pressure (51-180 kPa), achieving complete conversion with minimized ROS generation through optimized pH (7.0-8.0) and reducing agent supplementation. |